HomeProductsBioactive CompoundsMAPK/ERK PathwayMEKBms-599626
Chemical structure of CAS 714971-09-2

Bms-599626

CAS No.714971-09-2
MDL No.MFCD10565678
MFC27H27FN8O3
MW530.60
InChI KeyLUJZZYWHBDHDQX-QFIPXVFZSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.714971-09-2
Product NameBms-599626

Biological Targets

EGFR·ERBB2·ERBB4

Associated Conditions

Paraganglioma·neoplasm·cancer
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing.

Bioorganic chemistry • Vol. 153 • 2024
PMID: 39418845DOI: 10.1016/j.bioorg.2024.107874

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology • Vol. 23, Issue 2 • 2012
PMID: 21576284DOI: 10.1093/annonc/mdr137

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.

Journal of medicinal chemistry • Vol. 52, Issue 21 • 2009
PMID: 19821562DOI: 10.1021/jm9010065

Documentation